Drug intelligence / Profile preview

IB-AD

Development stage: Preclinical
Lead developer: Innobioscience
Modality: Small Molecules
Administration: Oral

Overview

IB-AD is an oral small molecule drug candidate developed by Innobioscience for the treatment of Alzheimer's Disease. It features a multi-target mechanism of action designed to modulate the Wnt/β-catenin signaling pathway, inhibit Glycogen synthase kinase-3 beta (GSK-3β), and engage Peroxisome proliferator-activated receptor gamma (PPAR-γ) pathways. This approach is intended to mitigate neurodegeneration and address tau-related pathology, which are central to the progression of Alzheimer's Disease. As of the latest pipeline information, IB-AD is in the preclinical stage of development.

Targets

GSK3 (Glycogen synthase kinase 3 beta)MAPT (Microtubule-associated protein tau)PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on IB-AD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IB-AD.

Explore the full profile